Cannabis Law Report

JULY 30, 2019

Following an encouraging initial US launch, GW Pharmaceuticals’s cannabidiol oral solution is also set to achieve European approval later in 2019. The US approval of Zogenix’s Fintepla, a potential competitor for GW’s drug, has been delayed but still lo… The European Pharmaceutical Review reports.

Epilepsy 40

Epilepsy Pharmaceutical Medicine Treatment 40

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. 30 May 2019.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Cannabis Law Report

SEPTEMBER 28, 2021

DUBLIN–(BUSINESS WIRE)–The “Epilepsy – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This Epilepsy – Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.

Epilepsy 40

Epilepsy Clinical Trials Research and Development Pharmaceutical 40

Peninsula Alternative Health

MAY 15, 2019

Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

MMJ Recs

NOVEMBER 20, 2023

Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition. Researchers have been conducting clinical studies to investigate the safety and efficacy of cannabinoid-based treatments. Image by Pfüderi from Pixabay.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Epilepsy Behav. Accessed October 17, 2022. 2021.108514.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JANUARY 18, 2022

.–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. About Virpax Pharmaceuticals. Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of epilepsy in children (a rare pediatric disease) and adults.

Safety 40

Safety Chronic Pain Research and Development Pharmaceutical 40

MMJ Recs

NOVEMBER 17, 2023

The community impact is visible in several key areas: Healthcare Advancements MMJ has expanded the range of treatment options available to patients, offering an alternative to conventional pharmaceuticals. MMJ is known for its efficacy in treating various medical issues, including chronic pain, epilepsy, multiple sclerosis, and more.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Enquiries: GW Pharmaceuticals plc.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

Veriheal

NOVEMBER 10, 2020

The experiment will allow participating companies to import cannabis and the companies who wish to participate in the experiment will be obliged to give participants free medical cannabis which has to comply with the pharmaceutical standards and good manufacturing practice. .

Chronic Pain 90

Chronic Pain Pharmaceutical Patients Epilepsy 90

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. The perception that CBD is a wonder-drug version of cannabis — particularly known for its uses to treat epilepsy — that doesn’t get you high. Shutterstock).

CBD 122

CBD Research and Development Epilepsy Extraction 122

The Cannigma

MARCH 7, 2022

When CBN was studied without barbiturates (prescription sedative medications typically used for epilepsy), the combination of CBN and THC produced greater sedation together than either cannabinoid alone. Preclinical studies by InMed Pharmaceuticals showed that CBN not only reduced markers of inflammation and pain, but also increased keratin.

THC 139

THC Sleep Clinical Trials Cannabinoids 139

Veriheal

MAY 17, 2021

Please don’t further the lie by voting for any form of legalization beyond the pharmaceutical remedies already available under state law.” She ends the column by stating “ I urge our legislators to abandon this legislation for the sake of our citizen’s health and safety.”.

Legalization 93

Legalization Pharmaceutical Therapy Chronic Pain 93

Kind Meds (Cannabis Education Blog)

JANUARY 9, 2019

Medical marijuana laws have changed dramatically across the country in recent years, and now cannabis pharmaceuticals appear to be the next big leap forward in cannabis law reform. Epidiolex has received FDA approval to treat Dravet Syndrome and Lennox-Gestaut Syndrome; two very rare forms of epilepsy that manifest in early childhood.

Research and Development 97

Research and Development Treatment Pharmaceutical Conditions 97

Cannabis Law Report

DECEMBER 28, 2021

–(BUSINESS WIRE)– #pharma –Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX) achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I About Virpax Pharmaceuticals. BERWYN, Pa.–(BUSINESS

Pharmaceutical 40

Pharmaceutical Research and Development Clinical Trials Chronic Pain 40

Veriheal

AUGUST 9, 2023

CBD, Trema micrantha, and the Study’s Significance CBD means cannabidiol , one of over a hundred compounds in the cannabis plant, and is widely celebrated as a potential treatment for a long list of health concerns, including chronic pain , epilepsy , i nsomnia , anxiety , and skin allergy.

CBD 96

CBD Cannabinoids THC Extraction 96

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Freedom Leaf

OCTOBER 15, 2018

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. The push for CBD is not surprising, whether it’s sold as a pharmaceutical drug or as a “dietary supplement” similar to gingko biloba or St.

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., About MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Cannabis Law Report

JUNE 20, 2019

Specifically, airmen are concerned about the safety of cannabidiol (CBD) oil use and how such use impacts an airman’s medical certificate. Be aware that federal law — not state law — governs FAA medical and pilot certification. One such compound being widely marketed is CBD oil. In other words, you know what you are getting.

THC 74

THC CBD Oil DEA 74

The Cannigma

JANUARY 16, 2023

1 Muscimol is a well-researched, natural compound and has been studied as a potential treatment for drug-resistant epilepsy, its potential effects on neurological disorders, and its pain-relieving abilities. Muscimol was the molecule used by scientists to develop numerous new pharmaceutical drugs aimed at targeting the GABA system.

Research and Development 127

Research and Development History Treatment Retail 127

TheAnswerPage

JUNE 12, 2022

Has the use of a transdermal gel for regional and systemic delivery of CBD been evaluated for the treatment of epilepsy? A transdermal gel for regional and systemic delivery of CBD (Zynerba Pharmaceuticals) is in clinical development for treatment of epilepsy, developmental and epileptic encephalopathy, fragile-X syndrome, and osteoarthritis.

Epilepsy 40

Epilepsy Topical Safety Treatment 40

TheAnswerPage

OCTOBER 11, 2021

Has the use of a transdermal gel for regional and systemic delivery of CBD been evaluated for the treatment of epilepsy? A transdermal gel for regional and systemic delivery of CBD (Zynerba Pharmaceuticals) is in clinical development for treatment of epilepsy, developmental and epileptic encephalopathy, fragile-X syndrome, and osteoarthritis.

Epilepsy 40

Epilepsy Topical Safety Treatment 40

Cannabis Law Report

FEBRUARY 1, 2022

Medical cannabis and psychedelics are being increasingly recognised by health professionals for their superior safety and efficacy compared to conventional pharmaceuticals. The recent multi-billion acquisitions of cannabis pharmaceutical companies demonstrate ever-increasing interest from Big Pharma players around the globe.”

Pharmaceutical 52

Pharmaceutical Medicine Safety Epilepsy 52

Cannabis Law Report

AUGUST 24, 2019

The report reveals… MGC Pharmaceuticals is set to kick off a controlled trial to discover if its medical cannabis product for the treatment of drug-resistant epilepsy has any impact on driving performance.

Epilepsy 45

Epilepsy Pharmaceutical Data Safety 45

Cannabis Law Report

DECEMBER 22, 2019

Cannabis-based medicine is to be fast-tracked into the NHS , allowing thousands of people to be prescribed the drugs, including children with severe epilepsy. But it has become apparent that doctors are unwilling to take the responsibility without more evidence on the effects and safety.

Epilepsy 45

Epilepsy Medicine Treatment Pharmaceutical 45

Cannabis Law Report

MARCH 6, 2020

” In 2018, Europe was responsible for 23.2% of the world’s pharmaceutical sales with the size of the market in the EU-5 ( United Kingdom , Germany , Spain , France , and Italy ) set to grow by 25% between 2017 and 2022. It’s safety and efficacy have not been confirmed by FDA-approved research.

Research and Development 59

Research and Development Marijuana Pharmaceutical Supply Chain 59

Cannabis Law Report

JANUARY 3, 2022

TASE: PNAX), a global pharma company that develops, manufactures and markets progressive cannabis-based products in pharmaceutical quality, announced today that it has received official approval for the EU-GMP standard for its production facility in Malta from EU Health Authority. SOURCE Panaxia Pharmaceutical Industries.

Pharmaceutical 52

Pharmaceutical Chronic Pain Extraction Epilepsy 52

Peninsula Alternative Health

MAY 15, 2019

Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy.

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

Healer

DECEMBER 17, 2021

The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. Epilepsy & behavior case reports 9 (2018): 10. Alsherbiny, Muhammad, and Chun Li. Medicines 6.1

CBD 98

CBD THC Conditions Medicine 98

Puff Puff Post

DECEMBER 28, 2018

Influencing how information is processed and how nerve cells and synapses in the brain interact, the exact function related to autism is still not well understood, and no pharmaceuticals around yet can ‘fix’ autism. million USD for their study regarding the safety and efficacy of CBD therapy for autism in children.

Treatment 76

Treatment Oil CBD Therapy 76

Cannabis Law Report

JANUARY 24, 2020

Additionally, severe refractory (treatment-resistant) epilepsy also qualifies. Two products were approved for use last year – High CBD Oil Drops from Aurora and CannEpil, which is produced by ASX-listed MGC Pharmaceuticals. A third has now been added to the list; an oral solution from Canada’s Tilray – THC10:CBD10.

Oil 45

Oil Epilepsy Conditions Treatment 45

SpeedWeed

AUGUST 1, 2021

This is one of more than a dozen third-party scientific investigations Charlotte’s Web is conducting on the efficacy and safety of our hemp extracts,” Charlotte’s Web CEO Deanie Elsner said in a press release. “We She was prescribed a variety of pharmaceutical drugs, with little success, if any. View original article.

Hemp 52

Hemp Extraction Agriculture Strains 52

Veriheal

NOVEMBER 2, 2020

The Australian Department of Health and parliament have not established a list of qualifying conditions, but are currently looking into research for conditions commonly treated with cannabis such as chronic pain, epilepsy, and multiple sclerosis amongst others.

Chronic Pain 52

Chronic Pain Strains Conditions Patients 52

Cannabis Law Report

DECEMBER 20, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. About Virpax Pharmaceuticals. Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of epilepsy in children (a rare pediatric disease) and adults.

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Data 40

Cannabis Law Report

DECEMBER 8, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. The results of this study underscore the safety of our spray film technology.”. About Virpax Pharmaceuticals. BERWYN, Pa.–(BUSINESS Mack, Chairman and CEO of Virpax. For more information, please visit www.virpaxpharma.com.

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Topical 40

Cannabis Law Report

JULY 13, 2019

We heard throughout our inquiry that some pharmaceutical companies were not willing to provide their product for trial,” the report says. However the problem in the U.K. is such special drugs are subject to stringent guidelines.

Research and Development 40

Research and Development Clinical Trials Epilepsy Patients 40